HC Wainwright Weighs in on Greenwich LifeSciences, Inc.’s Q1 2025 Earnings (NASDAQ:GLSI)

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) – Stock analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Greenwich LifeSciences in a research report issued to clients and investors on Wednesday, May 22nd. HC Wainwright analyst Y. Chen expects that the company will post earnings of ($0.17) per share for the quarter. HC Wainwright has a “Buy” rating and a $36.00 price objective on the stock. The consensus estimate for Greenwich LifeSciences’ current full-year earnings is ($0.76) per share. HC Wainwright also issued estimates for Greenwich LifeSciences’ Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.17) EPS and FY2025 earnings at ($0.70) EPS.

Greenwich LifeSciences Stock Performance

Shares of NASDAQ:GLSI opened at $13.40 on Thursday. Greenwich LifeSciences has a 1 year low of $7.58 and a 1 year high of $21.44. The stock has a market capitalization of $172.59 million, a P/E ratio of -18.61 and a beta of 1.55. The stock has a 50-day simple moving average of $15.28 and a 200-day simple moving average of $12.54.

Greenwich LifeSciences (NASDAQ:GLSI) last posted its quarterly earnings results on Monday, April 15th. The company reported ($0.21) EPS for the quarter.

Hedge Funds Weigh In On Greenwich LifeSciences

A hedge fund recently raised its stake in Greenwich LifeSciences stock. Vanguard Group Inc. increased its stake in shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) by 0.6% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 223,102 shares of the company’s stock after acquiring an additional 1,420 shares during the period. Vanguard Group Inc. owned approximately 1.73% of Greenwich LifeSciences worth $4,449,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Insider Transactions at Greenwich LifeSciences

In other news, CEO Snehal Patel bought 4,100 shares of the firm’s stock in a transaction dated Monday, March 4th. The stock was acquired at an average price of $13.03 per share, for a total transaction of $53,423.00. Following the acquisition, the chief executive officer now owns 5,340,277 shares of the company’s stock, valued at $69,583,809.31. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In the last quarter, insiders bought 11,100 shares of company stock worth $187,133. 52.86% of the stock is currently owned by company insiders.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.